WHAT THE TRIALS SHOW ~ EFFICACY
PT-141 Clinical Trials and Efficacy Endpoints
Two Phase 3 trials met their goals against placebo. The effect was statistically significant and clinically modest — and a published re-analysis argues it is smaller than it looks.
The short version
The PT-141 clinical trials that earned the drug its approval are two near-identical studies called RECONNECT, run in premenopausal women with low sexual desire. Both hit their two main targets: women reported more sexual desire and less distress about their low desire than women on placebo [3]. The catch is the size: the average improvement was small. The trials measure desire and distress with standard questionnaires — the FSFI and FSDS (the validated forms researchers use to score sexual desire and the distress that low desire causes) — and a published re-analysis argues the gains, while statistically real, may not amount to much a person would notice [9]. This page lays out both sides.
What were the results of the PT-141 clinical trials?
The pivotal evidence is the RECONNECT program: two identical Phase 3 randomized controlled trials in 1,267 premenopausal women with acquired, generalized HSDD, testing bremelanotide 1.75 mg subcutaneously, as needed, against placebo over 24 weeks [3]. Both trials met both coprimary endpoints. Pooled across the program, the change in the FSFI desire-domain score was +0.35 versus placebo (P<.001), and the change in FSDS-DAO item 13 — the question that measures distress about low desire — was -0.33 versus placebo (P<.001) [3]. The most common adverse events were nausea, flushing, and headache [3].
The durability evidence is the 52-week open-label extension, in which 684 women continued the drug. No new safety signals emerged, the desire improvements were sustained, and the most common drug-related treatment-emergent adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. Nausea was the principal tolerability issue [4].
What the trials show PT-141 does
In its approved population, the trials document two things and only two things with confidence: improved sexual desire and reduced desire-related distress, both versus placebo, both sustained over a year [3][4]. Those are the PT-141 benefits the evidence supports — stated as trial findings, not as a recommendation that any individual will experience them, and strictly within the premenopausal-HSDD indication.
The earlier human work pointed the same direction before Phase 3. A randomized, placebo-controlled, dose-finding study evaluated subcutaneous bremelanotide at 0.75, 1.25, and 1.75 mg in premenopausal women with female sexual dysfunction, and helped establish the 1.75 mg dose that advanced to Phase 3 [8]. Earlier still, an intranasal study in 18 premenopausal women with female sexual arousal disorder found a single 20 mg dose increased self-reported moderate-to-high sexual desire versus placebo (P=0.0114) [7]. All of this benefit sits inside the female indication; every male and erectile use remains off-label and investigational, and is discussed on the off-label male and erectile research page.
How big is the effect of bremelanotide on sexual desire?
Small — and that is the heart of the public argument over this drug. The integrated Phase 3 effects (FSFI-desire +0.35; FSDS-DAO item 13 -0.33) are statistically significant but modest in absolute terms [3]. A re-analysis of the Phase 3 HSDD trials argued the observed treatment effects on desire and distress were small and questioned their clinical meaningfulness — that is, whether a change of that size is one a woman would actually notice in her life [9].
This is the honest shape of the evidence: the approval is real, the statistical signal is real, and the magnitude is genuinely contested. A balanced reader should hold all three at once. A 2026 multidisciplinary panel on the evaluation and management of HSDD in women addressed the evidence-based use of approved pharmacotherapies, including bremelanotide, placing the drug within a wider clinical context rather than treating it as a settled win [15].
PT-141 for Women: The Approved HSDD Indication
The single FDA-approved use of PT-141 is PT-141 for women — specifically, acquired, generalized HSDD in premenopausal women, the population studied in RECONNECT [3][6]. "Acquired" means the low desire developed after a period of normal desire; "generalized" means it is not limited to a particular partner or situation. HSDD itself is a diagnosis of persistently low or absent sexual desire that causes marked personal distress and is not better explained by another condition or relationship problem [3].
Within that population, bremelanotide is the only melanocortin-based option, and it sits alongside flibanserin (the other approved HSDD medication) as a distinct mechanism — an as-needed, brain-acting injection rather than a daily oral drug [6]. Outside that population, the approval does not extend, and the evidence thins quickly: use in postmenopausal women, in men, or for erectile dysfunction is off-label, and the male/erectile data in particular remain early-phase and investigational.
Does PT-141 work?
In the approved population, yes — modestly, and with an asterisk. In the two Phase 3 RECONNECT trials in premenopausal women with HSDD, bremelanotide met both coprimary endpoints versus placebo [3]. The benefit was statistically significant but clinically modest, and a published re-analysis disputes its real-world size [9]. For any use outside that indication, there is no Phase 3 efficacy answer at all.